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Summar~ 
Sphingosine is a biologically active derivative of sphingomyelin. It affects diverse cellular functions 
and its mechanism(s) of action is poorly defined. Tumor necrosis factor o~ (TNFol) has recently 
been shown to rapidly induce sphingomyelin  turnover,  implicating this metabolic pathway in 
TNFo~  signal  transduction.  Because TNFot  is  known  to  induce prostaglandin  E2  (PGE2) 
production in human fibroblasts, we tested the effect of sphingosine  on TNFcc-induced  PGE2 
production. We found that sphingosine enhanced TNFot-induced PGE2 production by as much 
as 18-fold over TNFot alone. Sphingosine appeared to stimulate TNFot-induced PGE2 production 
independent of TNFc~-mediated interleukin 1 (IL-1) production, because anti-IL-1 antibodies and 
IL-1 receptor antagonist protein (IRAP) did not inhibit TNFc*-induced PGE2 production or the 
stimulatory effect of sphingosine.  TNFot stimulated PGE2 production to the same degree in 
normal and protein kinase C (PKC) downregulated cells in the presence and absence of sphingosine, 
indicating that neither TNFot nor sphingosine require active PKC to elicit their respective effects. 
The sphingosine  analogues stearylamine  and stearoyl-D-sphingosine had little or no effect on 
TNFo~-mediated PGE2 production, supporting a specific role for sphingosine in the activation 
process. Short-term (1 rain) exposure of cells to sphingosine dramatically increased TNFot-induced 
PGE2 production. A potential mechanism by which sphingosine could increase TNFo~-induced 
PGE2 production involves enhancement of phospholipase  A2 (PLA2) and/or cyclooxygenase 
(Cox) activity, the rate-limiting enzymes in PGE2 production. We found that both TNFot and 
sphingosine alone enhanced these enzymatic activities, and that sphingosine additively increased 
the effect of TNFc~ on phospholipase  A2 activity.  It appears that sphingosine  affects TNFol- 
induced PGE2 production via a mechanism that is independent of PKC involvement,  and that 
sphingosine  may function as  an  endogenous second  messenger  capable  of modulating the 
responsiveness of the cell to external  stimuli. 
S 
Phingosine,  a metabolite of sphingomyelin turnover (1), 
can elicit a variety of cellular responses including inhibi- 
tion of growth factor action (2, 3), modulation of receptor 
function (4-6), inhibition of platelet  and neutrophil func- 
tion (7, 8) and calmodulin dependent enzymes (9), antagonism 
of phorbol ester induced responses (10-12), and promotion 
of antitumor activity (1, 13). Many of the affects of sphingo- 
sine appear to be a direct consequence of the inhibition of 
protein kinase C (PKC) 1 activity (7, 8, 10, 11), a key regula- 
tory enzyme involved in signal transduction in a variety of 
physiological processes (14, 15). Although the full range of 
1  Abbreviations used in this paper: Cox, cyclooxygenase;  IILAE  IL-1 receptor 
antagonist protein; PGE2, prostaglandin Ez; PKC, protein kinase C; 
PLAz, phospholipase  A2. 
biochemical targets for sphingosine has yet to be identified, 
several PKC-independent mechanisms for sphingosine action 
have been recognized (16-18). The diverse effects of sphin- 
gosine suggest that it may act as an endogenous modulator 
of cell function, a second messenger molecule, generated as 
a result of agonist-stimulated sphingolipid turnover (1). How- 
ever, the mechanism(s) of sphingosine action and those signal 
transduction pathways that it modulates are not well defined. 
TNFot is a pluripotent cytokine secreted by macrophages 
in response to a variety of inflammatory agents (19). It has 
a broad range of in vivo activities as demonstrated by its ability 
to affect the growth, differentiation,  and function of virtu- 
ally every cell type investigated (20, 21). Cellular responses 
to TNFc~ are triggered by interaction of TNFot with high- 
affinity cell surface receptors (22, 23). Although sensitivity 
to TNFot can be modulated by regulation of receptor expres- 
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at the post-receptor level. Several lines of evidence  suggest 
the participation of protein kinases in TNFc~ signal trans- 
duction (24, 25), and other findings support protein kinase- 
independent mechanisms (26, 27). Recently, TNFol has been 
shown to stimulate sphingomyelin metabolism, suggesting 
that this pathway may be an important signaling mechanism 
mediating some of the many actions of TNFot (28). 
IL-1 and TNFol are known to elicit similar responses  in 
a variety of cell types, including stimulation of prostaglandin 
E2 (PGE2) production (29,  30).  Both cytokines are elabo- 
rated by mononudear cells in response to the same stimuli. 
They have similar functional profiles, molecular weights, and 
ionic characteristics  (31-34),  and further, TNFol can itself 
induce the production of IL-1 (35). Thus, specific responses 
of fibroblasts  to these cytokines are sometimes difficult to 
differentiate. We show here that sphingosine stimulates TNFo~- 
mediated PGE2 production via a PKC-independent pathway, 
at least in part, by stimulating phospholipase A2 (PLA2) ac- 
tivity. TNFc~-mediated Ibl production does not appear  to 
be involved in the process. Our observation that very short 
exposure of cells to sphingosine is sufficient to maximally 
stimulate TNFol-mediated PGE2 production, together with 
the previous observation that TNF-o~ rapidly induces the me- 
tabolism of sphingomyelin, is consistent with the concept 
that sphingolipid metabolites may play an important role as 
endogenous second messengers in regulating the ability of 
cells to respond to TNFo~ and, most likely, to other cytokines. 
Materials and Methods 
Cytokine Preparations and Antibodies.  Sphingosine from bovine 
brain sphingomyelin  was purchased from Sigma Chemical Co., (St. 
Louis, MO), and recombinant TNFce was from 8. & D Systems 
(Minneapolis, MN). mAbs to IL-lc~  and Ibl/~ were obtained from 
R & D Systems,  and IRAP (36) was the generous gift of  Dr. Daniel 
E.  Tracey of The Upjohn  Company  (Kalamazoo, MI).  PMA, 
stearoyl-D-sphingosine, and stearylamine were all obtained from 
Sigma Chemical Co. [3H]PGE2 was purchased from New England 
Nuclear (Boston, MA). PGE2 antiserums were obtained from Ad- 
vanced Magnetics, Inc. (Cambridge, MA). 
Fibroblasts Cell Lines and Culture.  Six different human foreskin 
fibroblast lines were employed in these studies. Human foreskin 
fibroblasts  were obtained and cultured as previously  described  (18). 
Where indicated ceils  were treated with growth factors, anti-Iblce 
and anti-IblB mAbs (10 and 100 #g/m1, respectively), IRAP (1 
ng/ml), PMA (100 nM final in DMSO), or aliphatic amines (10 
/~M), along with the appropriate vehicle  controls. Sphingosine  was 
always added as a complex with BSA, which was prepared by in- 
cubating equimolar amounts of BSA and sphingosine  in Tris buffer 
(pH 7.4) for 1 h at 37~  Incubations typically lasted 24 h after 
which  time the media were collected and assayed for PGE2 by 
ILIA. The effects of sphingosine and TNFce on cell viability were 
assessed by trypan blue exclusion.  At 10/~M sphingosine  and 1 ng/ 
ml TNFc~, neither cell  morphology nor viability  was affected  during 
the course of the experiments described. 
PGE2 RM.  This assay  is based upon the competition of cold 
(sample PGE2) with labeled PGE2 for anti-PGE2-antibody  binding 
sites as previously  described (18). The culture media were harvested 
from cells treated as indicated, and a 10-/~1 aliquot was added to 
ILIA assay  buffer (0.1 mM phosphate buffer, pH 7.4, containing 
0.9% sodium chloride, 0.1% sodium azide, and 0.1% gelatin). The 
sample was then mixed with the appropriate amount of labeled 
tracer and reconstituted antiserum. The mixture was allowed to 
equilibrate at room temperature for I h and then incubated over- 
night at 4~  Assay tubes were then placed in an ice bath,  and 
I ml of a cold charcoal-dextran suspension was added. After a 15- 
rain incubation, the tubes were centrifuged at 2,200 g for 10 rain 
at 4~  the supernatants were decanted into scintillation vials and 
counted using liquid scintillation. Percent binding was compared 
against a standard curve, and the amount of PGE2 in the sample 
was calculated. 
PKC Downregulation.  Confluent fibroblast cultures were pre- 
treated with 1/~M PMA for 24 h at 37~  After this treatment, 
the ceils were washed three times with Eagle's minimal essential 
medium (EMEM), and 0.5 ml fresh EMEM containing 1% FCS 
was added. The cells were then treated as indicated and PGEz was 
measured as described above. 
PLA2 Assay.  The assay used to measure PLA2 activity in cell 
extracts is a modification of a procedure previously described by 
Ballou, et al. (37-39). Briefly,  confluent fibroblast  monolayers  from 
six-well plates were washed several times with 2 ml of 100 mM 
Tris, pH 7.0. The cells were scraped from the plate in 120/~1 of 
the same buffer, sonicated for 15 s, and centrifuged at 15,000 g 
for 15 min. The pellet was discarded and the supernatant fraction 
kept on ice until assayed  for PLA2 activity. Each assay contained 
40 /~1 of the  supernatant fraction ('~50  #g of protein),  1-pal- 
mitoyl-2-[1-14C]arachidonylphosphatidylcholine  (50,000 cpm  in 
5/zl DMSO), and 1 mM CaCh. The assay  was initiated by adding 
10/~1 of a reaction mixture such that the final concentration of 
each component was as described  above. Tubes were mixed  by vortex 
and incubated in a 37~  water bath for 30 min. The reaction was 
stopped by the addition of 50/~1 of ethanol containing 2% acetic 
acid. Each tube was mixed by vortex and 50/zl was applied to a 
silica gel G TLC plate and developed in ethyl acetate/acetic acid 
(99:1). As indicated for certain experiments, cells were pretreated 
with TNFc~ and/or sphingosine for 18 h before preparation of the 
extract. 
Cox Assay.  The procedure for obtaining the cell extract was 
the same as for the PLA2 assay. Each Cox assay contained 40 #1 
of the cell extract and 1/~M epinephrine/1 mM phenol in 100 mM 
Tris (pH 8.5). The reaction was initiated by adding 10 #1 1 mM 
arachidonic acid in ethanol to each tube. The reaction was allowed 
to proceed for 15 rain at 37~  and stopped by the addition of 10 
#1 25 mM FeC12-4HzO. Then, the samples were stored at  -20~ 
until PGE2 was measured by RIA as described above. 
Statistical Analysis.  Student's t test was used for all statistical 
analyses. 
Results 
Sphingosine Potentiates TNFol-induced  PGE2 Production in 
Human Fibroblasts.  In a series of experiments we evaluated 
the effect of TNFce and sphingosine on PGE2 production in 
human fibroblasts. In six cell lines tested, we consistently ob- 
served a dramatic increase in the amount of PGE2 produced 
in response  to TNFce if sphingosine was also present. Fig. 
1 shows that at 10/~M sphingosine, approximately 18-fold 
more PGE2 was produced in response  to  1 ng/ml TNFce 
than in the absence of sphingosine. Sphingosine alone had 
comparatively little effect on PGE2 production at any con- 
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Figure  1.  Sphingosine potentiates TNFr~-induced PGE2 production. 
Confluent human foreskin fibroblasts were treated with TNFc~ (1 ng/ml) 
and the indicated concentrations of sphingosine.  PGE2 was measured by 
ILIA as described in Materials and Methods. The results are expressed as 
ng of PGE2 produced per 100/~1. Similar results were obtained in two 
additional experiments. Standard deviations between duplicate assays for 
each experimental treatment were less than 5%. 
centration  tested.  TNFc~-mediated PGE2 production  in- 
creased as a function of sphingosine concentration. However, 
concentrations of sphingosine over 25/zM were cytotoxic, 
as previously reported (18). Although we observed some de- 
gree of quantitative variability with respect to PGE2 produc- 
tion among the cell lines examined, the combination of TNFol 
and sphingosine invariably resulted in a synergistic increase 
of PGE2 production. In a series of six separate experiments 
each  using a  different fibroblast  cell line,  we observed a 
sphingosine-mediated  increase  in  TNFc~-induced  PGEz 
production ranging from 3.5- to 17.7-fold over TNFc~ levels 
alone. The lowest mean increase (3.5-fold) induced by TNFol 
and  sphingosine  over  TNFcr  controls  was  statistically 
significant  (Student's t test, p <  0.005). 
IRAP and Anti-IL I Antibodies Do Not Inhibit TNF~/Sphin- 
gosine Synergy.  TNFc~ has been shown to induce Ibl syn- 
thesis by certain target cells (35). Therefore, to rule out poten- 
tial effects of II.-1 on TNFc~-mediated PGE2 production, we 
tested the effects of sphingosine and TNFo~ in the presence 
of neutralizing Ibl (c~ and B) mAbs and IRAP. We added 
IRAP (1 ng/ml), which blocks the action of IL-1 by binding 
to IL-1 receptors with about the same af~nity as II.-1 (36), 
anti-IL-lot (10/~g/ml), and anti-Ibll3 (100/~g/ml), an amount 
that totally blocked the effect of exogenously added I1.-1 (1 
ng/ml) on PGE2 production (data not shown). Fig. 2 shows 
that when IRAP or anti-tbl antibodies are added to the in- 
cubation medium, TNF~-induced PGE2 production remains 
stimulated by sphingosine. Control assays containing com- 
binations of anti-IL-1, IRAP, sphingosine, and each alone, 
resulted in no effect on basal PGE2 production. Thus, sphin- 
gosine and TNFo~ appear to increase PGEz production in 
human fibroblasts  independent of IL-1 effects, although we 
cannot rule out the potential effects of intracellular I1-1. 
The Effect of Sphingosine on PMA  and  TNFol-Mediated 
PGE2 Production After PKC Downregulation.  Many effects of 
sphingosine (7, 8, 10, 11) and TNFc~ (24, 25) appear to be 
a direct consequence of PKC inhibition or activation, respec- 
tively.  PMA is  a potent activator of PKC  (15); however, 
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Figure 2.  IRAP and mAbs against Ibl do not inhibit TNFceinduced 
PGEz production. Confluent fibroblast cultures (24-well) were treated as 
indicated. After 24 h PGE2 was measured by RIA as described in Materials 
and Methods.  Untreated control PGE2 levels were normalized to 1.0, and 
the fold stimulation by each treatment was calculated.  Each value is the 
mean of three additional experiments from two identically treated wells 
_+ SD. The concentration of each addition was: anti-IbltS, 100 #g/ml; 
anti-II:l~, 10 #g/ml, IRAP, 1 ng/ml; sphingosine, 10 #M; TNFcr  1 rig/m1. 
prolonged exposure to PMA downregulates PKC activity in 
human cells (40, 41). Therefore, we compared the effects of 
sphingosine and TNFo~ on PGEz production in normal and 
PKC-deficient cells. Fig. 3 shows that TNFc~ alone stimu- 
lates PGE2 production equally in control and PKC down- 
regulated cells. As expected, PMA stimulates PGE2 produc- 
tion in normal cells but not in cells with downregulated PKC 
activity.  Interestingly, the combination of PMA and sphin- 
gosine, both of which stimulated some PGE2 alone, resulted 
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Figure  3.  The  effect  of TNF~  PMA,  and  sphingosine  on  PGE2 
production in normal and PKC downregulated fibroblasts. Confluent fibro- 
blast cultures were pretreated with 1/zM PMA for 24 h. Cells were then 
thoroughly washed and incubated with the following additions for 24 h: 
PMA, 100 riM, TNF~  1 ng/ml; sphingosine, 10 IzM. PGE2 was mea- 
sured by RIA as described in Materials and Methods. The results are ex- 
pressed as nanograms of PGE2 produced per 100/zl.  Each value represents 
the mean _+ SD of three experiments from identically treated duplicate wells. 
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mented opposing effects on PKC activity. Sphingosine dra- 
matically  enhanced  TNFc~-induced  PGE2  production  in 
normal cells, and this effect was not significantly decreased 
in cells with downregnlated  PKC activity, suggesting that 
in this case sphingosine provides a metabolic signal to the 
cell that  enhances TNFc~-mediated PGE2 production inde- 
pendent of any effects  that  sphingosine  may have on PKC 
activity. 
Specificity of the  Sphingosine Effect.  To  determine  the 
specificity of the stimulatory effect of sphingosine on TNF- 
o~-mediated  PGE2 production,  we tested the ability of two 
sphingosine  analogues,  stearoyl-D-sphingosine  and  stearyl- 
amine,  to  modulate  TNFc~-mediated  PGE2  production. 
Stearoyl-D-sphingosine lacks a free amino group and stearyl- 
amine has an alkyl chain length similar to sphingosine, but 
lacks both hydroxyl groups. Fig. 4 shows that in comparison 
to the ability of sphingosine to strongly potentiate TNFc~- 
mediated PGE2 production, stearylamine has some stimula- 
tory effect, and stearoyl-o-sphingosine does not show any syn- 
ergy with TNFc~. 
Time Course of Sphingosine-mediated Potentiation of TNFot- 
induced PGE2 Production.  To examine the temporal relation- 
ship between sphingosine treatment and its stimulatory effect 
on  TNFc~-induced  PGE2  production,  we  incubated  cells 
with sphingosine for the times indicated in Fig. 5, washed 
them with fresh culture media, and then treated them with 
TNFot (1 ng/ml)  for 24 h.  Fig.  5 shows that  the effect of 
sphingosine  on  TNFc~-mediated  PGE2  production  is  ex- 
tremely rapid.  After only a 1-min exposure to sphingosine, 
TNFc~-mediated PGE2 production was enhanced to 90% of 
maximal and to 100% after a 5-min exposure. TNFot-mediated 
PGE2  production  decreased  after  1  h  preincubation  with 
sphingosine, and longer pre-incubations resulted in progres- 
sively lower levels  of PGE2,  returning  to basal levels after 
24 h of exposure to sphingosine.  These results indicate that 
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Figure 4.  The effect  of TNFot, sphingosine, sphingosine analogues, on 
PGE2 production. Confluent cultures of human fibroblasts were treated 
as indicated. After 24 h PGE2 was measured by RIA as described in 
Materials and Methods. The results are expressed as nanograms of PGE2 
produced per 100/~1. Each value is the mean +_ SD of three experiments 
from identically treated duplicate wells. The concentration of each addi- 
tion was: TNFot, 1 ng/ml; sphingosine, 10/~M; stearylamine, 10/~M; 
stearoyl-D-sphingosine, 10/~M. 
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Figure 5.  The effect  of sphingosine pretreatment on TNFcz-mediated 
PGE2 production. Confluent fibroblast cultures were exposed to sphin- 
gosine (10/~M) for the times indicated. Each well was then extensively 
washed to remove  any remaining sphingosine. Each well was then treated 
with TNFc~ (1 ng/ml). Control wells were treated with sphingosine or 
TNFot alone and with sphingosine/TNPc~  combination. After 24 h PGE2 
production was measured  as described  in Materials and Methods. The results 
are expressed as nanograms of PGE2 produced per 100/~1. Each value 
represents the mean of triplicate assays from two separate wells _+ SD. 
PGE2 production was 0.4 _+ 0.14 ng/100 #1 in control wells treated with 
sphingosine alone, 1.4 +_ 0.28 ng/100/zl in wells treated with TNFot 
alone (time zero) and 5.7 + 0.14 ng/100/~1 in wells treated with sphingo- 
sine and TNFc~ at the same time. 
the effects of sphingosine on TNFot-induced PGE2 produc- 
tion are rapidly manifested and relatively transient. The tran- 
sient nature of the sphingosine effect may be due to its rapid 
metabolism to an inactive metabolite by the cell. 
The Effect of TNFot and Sphingosine on PLA2 and Cox Ac- 
tivity in Human  Fibroblasts.  Cytokine-induced  PGE2  pro- 
duction in human fibroblasts is regulated by the availability 
of arachidonic acid,  released from phospholipids by the ac- 
tion of PLA2, and on its conversion to PGE2 by Cox (42). 
To directly assess the effect of sphingosine  and TNFc~ on 
PLA2 and Cox activity, we prepared an extract from soni- 
cated fibroblasts using untreated cells and cells treated for 18 h 
with TNF~,  sphingosine or both. Fig. 6 shows that PLA2 
activity in cells pretreated with sphingosine (10 #M) and/or 
TNFot  (1 ng/ml)  is significantly  higher  than basal PLA2. 
Moreover, PLA2 activity derived from cells pretreated with 
both sphingosine and TNFc~ is significantly higher than in 
cells pretreated with TNFot alone (p < 0.05). Similarly,  Cox 
activity is significantly higher in cells treated with sphingo- 
sine and TNFc~ when compared with the activity measured 
in untreated ceils (p < 0.001), but not when compared with 
activity in cells  treated with  TNFot alone. 
Discussion 
Sphingolipids have been implicated in modulating many 
diverse cellular processes, including cellular communication, 
transformation,  proliferation,  differentiation,  and receptor 
function  (1, 43, 44).  The  mechanism(s)  of action and the 
signal transduction  pathways modulated by these complex 
lipids remain poorly understood.  Although much evidence 
suggests that  sphingosine is a potent inhibitor  of PKC ac- 
tivity (1, 13), other studies indicate that sphingosine has bio- 
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Figure 6.  The effect of TNFc~ and sphingosine on Cox and PLA2 ac- 
tivities.  PLA2 and Cox activities were measured as described in Materials 
and Methods. PGE2 production was  measured by RIA.  Confluent cul- 
tures of human fibroblasts were pretreated with TNF~x and/or sphingo- 
sine for 18 h before preparation of the supernatant fraction. The concen- 
tration of each  addition was:  TNFot,  1  ng/ml;  sphingosine 10 #M. 
Untreated control PLA2, Cox, and PGE2 levels were normalized to 1.0, 
and the fold stimulation by each treatment was calculated.  Each value is 
the mean of three experiments from two identically treated wells  +_ SD. 
logical effects which are, at least in part, independent of the 
PKC pathway (4, 5, 16, 18). Thus, caution has been urged 
in the use of sphingosine as a reagent to inhibit PKC and 
further, the possibility that sphingosine may not be a physio- 
logical modulator of PKC activity must be considered. The 
findings presented here suggest that sphingosine may be in- 
volved in modulating the responsiveness of the cell to TNFo~ 
Sphingosine has also been implicated as a modulator of the 
actions of epidermal growth factor (4), ILl (18), and most 
likely, other cytokines yet to be identified. 
Sphingomyelin turnover involves the hydrolysis of sphin- 
gomyelin to ceramide and phosphorylation  by a neutral sphin- 
gomyelinase. Some have suggested that this is an important 
biochemical pathway in regulating a variety of cell functions 
(45).  It has been demonstrated recently that TNFol causes 
an early and reversible sphingomyelin  hydrolysis in HL-60 cells 
accompanied by the concomitant generation of ceramide that 
subsequently downregnlates mRNA production for the c-myc 
protooncogene (28).  A variety of other biologically active 
sphingolipid metabolites, such as sphingosine (4,  18) and 
sphingosine-l-phosphate (43) are also produced during sphin- 
gomyelin turnover. Further, sphingosine may be converted 
to ceramide or sphingosine-l-phosphate, thus complicating 
determination of the specific effects of these compounds. 
Clearly, each of these metabolites may modulate a wide va- 
riety of cellular responses including the ability of certain inflam- 
matory cytokines to induce PGE2 production as shown here. 
The ability of TNFot to affect the growth, differentiation, 
and various other functions of virtually every cell type inves- 
tigated, appears to be largely determined at the postreceptor 
level. However, little is known about the precise intracellular 
pathways which mediate TNFol signal transduction. The effect 
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of TNFc~ on PKC activation is controversial but several  reports 
suggest that PKC activation may play a major role in TNF~x 
signal transduction in some (24, 25, 34), but not all target 
cells (26). With respect to transcriptional control, the rela- 
tionship between TNFol and the activation or repression of 
specific genes remains to be elucidated. In certain cell types 
(Jurkat and K562), TNFcx activates transcription factor NFkB 
via a PKC-independent pathway (27), further indicating that 
TNFo~ signal transduction does not necessarily require the 
involvement of PKC. 
The fact that TNFo~ and IL-1 share many functional char- 
acteristics  (including the stimulation of PGE2 production) 
led us to test the effect of sphingosine on TNFo~-mediated 
PGE2 production in order to determine whether similar 
mechanisms were involved in TNFo~- and IL-l-induced PGE2 
production. Recently we showed that sphingosine greatly 
potentiates  IL-l-mediated  PGE2 production  in  human 
fibroblasts independent of PKC activation (18). In fact, the 
downregulation of PKC activity by prolonged exposure to 
PMA (40, 41) mimicked the effect of sphingosine, suggesting 
that active PKC may actually  inhibit IL-l-mediated PGE2 
production, and that the stimulatory effect of sphingosine 
on IL-l-mediated PGE2 production was  due in part to its 
ability to inhibit PKC activity.  Conversely, with respect to 
sphingosine and TNFol, the inhibition of PKC activity by 
prolonged exposure to PMA had no effect on TNFoe-mediated 
PGE2 production in the presence or absence of sphingosine. 
These findings clearly suggest that some factor,  or factors, 
not involving the PKC pathway, are responsible for the poten- 
tiation  of TNF-cz-mediated  PGE2 production  by  sphin- 
gosine. 
The synergistic behavior of sphingosine and TNFcx  on 
PGE2 production appears to be independent of the poten- 
tial effects of TNFo~-induced IL-1 synthesis. Anti-IIAol, and 
anti-Ibl~ antibodies and IR.AP did not inhibit TNFoMnduced 
PGE2 production or the stimulatory effect of sphingosine, 
yet they completely blocked the effects of exogenously-added 
IL-1. Together, these results support the conclusion that TNFo~ 
acts independently of TNFc~-mediated IL-1 production, not 
only because  the  effects  of sphingosine and  TNFo~  are 
manifested quite rapidly but because, as previously shown, 
the time course of IL-l-mediated PGE2 production in cells 
preincubated with sphingosine (18) differs significantly from 
that of TNF~. Whereas sphingosine exhibits a rapid, tran- 
sient effect on TNFoe-induced PGE2 production, its effect on 
IL-1 mediated PGE2 production was less rapid, but more sus- 
tained. This difference may be because although TNFcx seems 
to act entirely independently of PKC, IL-1 mediated PGE2 
production may be downregulated by active PKC, and the 
inhibition of PKC by sphingosine requires a longer period 
of time to  achieve  (18). Clearly,  sphingosine potentiates 
PGE2 production in response to TNFcz or IL-1. However, 
the mechanism of sphingosine action appears to differ de- 
pending upon the external stimulus. Thus, the effects of sphin- 
gosine on cytokine-mediated PGE2 production are complex 
and cannot be attributed to any single biochemical event or 
process. 
The precise mechanism by which sphingosine potentiates TNFc~-induced PGEz production remains unclear. Previous 
data obtained in studies using IL-1- and sphingosine-treated 
fibroblasts  showed that  PLA2  activity derived from these 
cells was significantly higher than that detected in extracts 
obtained from cells treated with Ibl  or sphingosine alone 
(18). Recently, it has been reported that both TNFol and Ibl 
increase PLA2 mRNA levels and secretion of PLA2 from the 
cell  (46).  We  show  here  that  TNFo~  and  sphingosine 
significantly increase endogenous PLA2 activity over TNFot 
levels. While II.-1 has been shown to induce the synthesis 
of Cox  (42),  similar  studies using TNFot  have not been 
reported. The data presented here indicate that TNFot alone 
significantly increases Cox activity compared to control levels 
but sphingosine only slightly enhances the TNFot effect on 
Cox activity. On the basis of observations such as these, and 
because increased PGE2 production is likely to be dependent 
upon  increased PLA2  and Cox  activities,  we hypothesize 
that TNFol and sphingosine synergistically stimulate PGE2 
production in human fibroblasts, at least in part, by increasing 
arachidonic acid mobilization via TNFc~ and sphingosine- 
enhanced PLA2 activity, providing more substrate (arachi- 
donic acid) for conversion to PGE2 by Cox. Even slight in- 
creases in PLA2 and/or Cox activity could account for the 
observed increase in PGE2 production in response to TNFot 
and sphingosine because end product (PGE2) is allowed to 
accumulate over a relatively long period of time (24  h). 
The  finding  that  sphingosine  dramatically  potentiates 
TNFc~-mediated PGE2 production could be very important 
relative to our understanding of the pathophysiologic mech- 
anisms that mediate a variety of inflammatory processes. The 
role of PGE2, and other prostanoids, in inflammation is well 
established and its effects are known to include the media- 
tion of pain,  vasodilation, increased vascular permeability, 
and alterations in immune cell functions. Because sphingo- 
sine, and perhaps other sphingolipid metabolites, can so pro- 
foundly enhance cytokine-induced PGE2 production, it is in- 
teresting to speculate that the elevated levels of PG production 
commonly associated  with inflammatory disorders such as 
rheumatoid arthritis may not result from the overproduction 
of inflammatory cytokines by mononuclear cells, but rather, 
from increased sphingomyelin turnover in the target cell which 
can dramatically potentiate the response of the cell to other- 
wise normal levels of cytokine. 
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